Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPF induction chemotherapy followed by weekly cisplatin chemoradiation for larynx preservation in locally advanced laryngeal cancer
ACTRN12610000856011Phase 2Not yet recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in laryngeal cancer and head and neck cancer (HNC), sponsored by Shiraz University of Medical Sciences. Primary endpoint: Clinical response rate. Planned start Nov 2010; status: not yet recruiting.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
laryngeal cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on ACTRN12610000856011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000856011.